Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Income towards Parent Company (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Income towards Parent Company for 7 consecutive years, with -$236.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company fell 130.95% year-over-year to -$236.6 million, compared with a TTM value of -$682.7 million through Dec 2025, down 111.98%, and an annual FY2025 reading of -$682.7 million, down 111.98% over the prior year.
  • Income towards Parent Company was -$236.6 million for Q4 2025 at Avidity Biosciences, down from -$174.1 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$23.8 million in Q1 2021 and bottomed at -$236.6 million in Q4 2025.
  • Average Income towards Parent Company over 5 years is -$75.4 million, with a median of -$52.2 million recorded in 2023.
  • The sharpest move saw Income towards Parent Company crashed 291.8% in 2021, then dropped 2.57% in 2023.
  • Year by year, Income towards Parent Company stood at -$38.5 million in 2021, then tumbled by 31.07% to -$50.5 million in 2022, then fell by 19.59% to -$60.3 million in 2023, then tumbled by 69.81% to -$102.5 million in 2024, then tumbled by 130.95% to -$236.6 million in 2025.
  • Business Quant data shows Income towards Parent Company for RNA at -$236.6 million in Q4 2025, -$174.1 million in Q3 2025, and -$156.7 million in Q2 2025.